» Articles » PMID: 9569948

Cancer in End-stage Renal Disease: Potential Factors Involved -editorial-

Overview
Journal Am J Nephrol
Publisher Karger
Specialty Nephrology
Date 1998 May 7
PMID 9569948
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Increased incidence of cancer at various sites is observed in patients with end-stage renal disease (ESRD). In particular, lymphomas and carcinomas of the kidney, prostate, liver and uterus show an enhanced prevalence in these subjects compared with the general population. A multitude of factors directly or indirectly associated with the renal disease and the treatment regimens may contribute to the increased tumor formation in these patients. Impaired function of the immune system and of DNA repair mechanisms as well as reduced antioxidant defense, accumulation of carcinogenic compounds partly due to reduced renal elimination as well as chronic infections and inflammations are found more frequently in patients with ESRD compared with the general population and may act in concert to accelerate malignant transformation and tumor formation.

Citing Articles

Maintenance avelumab therapy for urothelial carcinoma in a hemodialysis patient: a case report.

Kamitani R, Matsumoto K, Yokota K, Hirai S, Komori T, Kamisawa K Int Cancer Conf J. 2024; 13(1):58-62.

PMID: 38187180 PMC: 10764676. DOI: 10.1007/s13691-023-00636-4.


Influenza vaccination is associated with lower risk of renal cell carcinoma among chronic kidney disease patients: a population-based cohort study.

Lin C, Zheng J, Tzou K, Fang Y, Kao W, Lin H Clin Kidney J. 2023; 16(11):1936-1946.

PMID: 37915887 PMC: 10616448. DOI: 10.1093/ckj/sfad110.


Investigation of XPD, miR-145 and miR-770 expression in patients with end-stage renal disease.

Citak E, Yalin S, Altiparmak M, Guven M Mol Biol Rep. 2023; 50(8):6843-6850.

PMID: 37392287 DOI: 10.1007/s11033-023-08608-w.


Effects of p-cresol, a uremic toxin, on cancer cells.

Chen X, Xiang F, Cao X, Zou J, Zhang B, Ding X Transl Cancer Res. 2023; 12(2):367-374.

PMID: 36915599 PMC: 10007878. DOI: 10.21037/tcr-22-2042.


Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.

Wang I, Yu T, Yen T, Lin C, Li C, Hsu C Int Urol Nephrol. 2023; 55(9):2267-2274.

PMID: 36859625 DOI: 10.1007/s11255-023-03534-z.